Skip to main content

5 Top Stock Gainers for Monday: SPX Flow, Five9, Cytokinetics

SPX Flow, Five9, Cytokinetics, NRx Pharmaceuticals and Chewy are five top stock gainers for Monday.
  • Author:
  • Publish date:

Stocks finished sharply lower Monday as investors weighed how rising COVID-19 cases might affect the economic recovery in the U.S. and globally.

Here are some of the top gainers for Monday:

1. SPX Flow | Increase 22%

SPX Flow  (FLOW) jumped after the industrial-equipment producer again rejected a takeover proposal from pumps and compressors manufacturer Ingersoll Rand  (IR)

The most recent bid was $85 a share, which SPX rebuffed on June 21. On May 27, SPX Flow had turned down an offer of $81.50 a share from Ingersoll Rand.

2. Five9 | Increase 5.9%

Shares of Five9  (FIVN)  climbed after Zoom Video Communications  (ZM) agreed to buy the call center operator for just under $15 billion. 

The purchase expands Zoom's total addressable market, including individual and enterprise customers, by around $24 billion.

3. Cytokinetics | Increase 40%

Cytokinetics  (CYTK)  leaped after the biopharma reported positive results from a Phase 2 trial of its heart disease treatment and said the results supported progression to a Phase 3 trial. 

The company unveiled positive top-line results from Cohorts 1 and 2 of CK-274, which is being developed to treat hypertrophic cardiomyopathy.

4. NRx Pharmaceuticals | Increase 45%

Shares of NRx Pharmaceuticals  (NRXP)  after the company presented evidence that its treatment, Zyesami, helps prevent so-called cytokine storm in patients with COVID-19. 

Cytokine storm occurs when an infection triggers the immune system to flood the bloodstream with inflammatory proteins called cytokines, which can kill tissue and damage organs.

5. Chewy | Increase 6.8%

Chewy  (CHWY)  rose after Exane BNP Paribas initiated coverage of the online pet-products provider with an outperform rating and $101 price target. 

Last month, Chewy swung to a surprise fiscal first-quarter profit from a year-earlier loss on 32% higher revenue.